F3 Specific Neutra™ Antibody Products

Product list

Tissue Factor or Coagulation Factor III (F3) is a glycoprotein situated on the cellular surface. F3 facilitates the initiation of blood coagulation cascades and serves as the high-affinity receptor for coagulation factor VII. Tissue factor facilitates the initiation of blood coagulation cascades and serves as the high-affinity receptor for coagulation factor VII. F3 comprises three distinct domains: cytoplasmic, extracellular, and transmembrane domain. Notably, F3 is unique in the coagulation pathway as no congenital deficiency has been reported for it. Here we provide a comprehensive range of well-developed anti-F3 antibodies for research purposes, encompassing anti-F3 monoclonal antibodies, antibody-drug conjugates (ADCs), and anti-F3 neutralizing antibodies.

Its Gene ID: 2152, UniProtKB ID: P13726, and OMIM ID: 134390.

Involved Pathway of F3

In various cancer types, F3 contributes to progression, invasion, metastasis, and angiogenesis through activation of signaling pathways. The F3 proteolytic pathway, facilitated by factor VIIa, influences angiogenesis. Tumor cell surface F3 expression elevates VEGF expression, promoting angiogenesis. F3's cytoplasmic domain activates GTPase, Rac-1, MAPK, and p38, facilitating tumor cell migration. Additionally, F3's cytoplasmic domain regulates VEGF expression and calcium pumps in monocytes.

Fig.1 F3 related pathways. (Ahmadi, et al., 2023) Fig.1 Impact of factors on F3 gene and tissue factor-mediated signaling pathways in cancer progression.¹

Therapeutic Applications of Anti-F3 Antibodies Across Disorders

Numerous investigations have evaluated the anti-tumor efficacy of ADCs across diverse solid tumor types.

Inhibition of Pancreatic Cancer Progression by Targeting Secreted F3 with Neutralizing Antibodies

AsTF, a secreted variant of F3, triggers blood coagulation in patients exhibiting elevated F3 expression levels in various solid tumors like pancreatic ductal adenocarcinoma (PDAC). Consequently, a neutralizing antibody specific to AsTF holds the potential to impede the spread and advancement of PDAC.

Fig.2 The impact of anti-F3 variant antibody on growth of orthotopically implanted human PDAC cells. (Unruh, et al., 2016) Fig.2 Investigating the impact of anti-AsTF antibody on growth of orthotopically implanted human PDAC cells in nude mice.²

Targeting F3 to Counter Thromboembolic Complications in Advanced Cancer

Thromboembolic complications are commonly linked with advanced cancer stages. F3 is known to be upregulated in various tumor types and is present on both tumor cells and tumor vasculature. While the precise mechanisms remain unclear, F3 expression on tumor cells can initiate intracellular signaling cascades via diverse pathways, ultimately promoting tumor angiogenesis, proliferation, and metastasis. Prophylactic treatment with a humanized anti-human F3 antibody has demonstrated efficacy in inhibiting experimental lung metastasis of human breast carcinoma cells and reducing tumor incidence and growth in orthotopically implanted breast carcinoma cells.

Creative Biolabs offers a diverse selection of more than 30 anti-F3 antibody products, meticulously engineered using recombinant techniques. Moreover, customization options are accessible to tailor F3-based bispecific antibodies to address specific needs.

REFERENCES

Ahmadi, Seyed Esmaeil, et al. "Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer." Biomarker Research 11.1 (2023): 60.
Unruh, Dusten, et al. "Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma." Oncotarget 7.18 (2016): 25264.

Show More Close